Introduction: Fatty acid–binding protein 3 (FABP3) is a biomarker of neuronal membrane disruption, associated with lipid dyshomeostasis—a notable Alzheimer's disease (AD) pathophysiological change. We assessed the association of cerebrospinal fluid (CSF) FABP3 levels with brain amyloidosis and the likelihood/risk of developing amyloidopathy in cognitively healthy individuals. Methods: FABP3 levels were measured in CSF samples of cognitively healthy participants, > 60 years of age (n = 142), from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). Results: FABP3 levels were positively associated with baseline brain amyloid beta (Aβ) load as measured by standardized uptake value ratio (SUVR, standardized β = 0.22, P =.009) and predicted the change in brain Aβ load (standardized β = 0.32, P =.004). Higher levels of CSF FABP3 (above median) were associated with a likelihood of amyloidopathy (odds ratio [OR] 2.28, 95% confidence interval [CI] 1.12 to 4.65, P =.023). Discussion: These results support inclusion of CSF FABP3 as a biomarker in risk-prediction models of AD.
CITATION STYLE
Dhiman, K., Villemagne, V. L., Fowler, C., Bourgeat, P., Li, Q. X., Collins, S., … Gupta, V. (2022). Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring, 14(1). https://doi.org/10.1002/dad2.12377
Mendeley helps you to discover research relevant for your work.